SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% ...
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded ...
Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class ...
AbbVie introduces Birdies for Brain Health, a purpose-driven PGA TOUR campaign that turns birdies into awareness and support for people living with brain health conditions and their care ...
Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival ...
New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive ...
Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, ...
R&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-based innovation shaping regenerative aesthetics. A featured SkinMedica® R&D panel on ...
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable November 16, 2026, to stockholders of record at ...
For further information: Media: Gabby Tarbert, (224) 244-0111; Investors: Liz Shea, (847) 935-2211; Todd Bosse, (847) 936-1182; Jeffrey Byrne, (847) 938-2923 The information in the press releases on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results